Aterosclerosi, cancro e inibitori dei checkpoint immunitari
Maria Laura Canale(Ospedale Versilia), Massimo Grimaldi(Ospedale Generale Regionale Francesco Miulli), Fabrizio Oliva(Associazione Nazionale Medici Cardiologi Ospedalieri), Luigi Tarantini(Santa Maria Nuova Hospital), Giuseppina Gallucci, Stefania Angela Di Fusco(ASL Roma), Alessandra Greco(St. Catherine University), Irma Bisceglia(Azienda Ospedaliera San Camillo-Forlanini), Fabiana Lucà(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Michele Massimo Gulizia(Ospedale Garibaldi), Furio Colivicchi(Ospedale San Filippo Neri), Domenico Gabrielli(Azienda Ospedaliera San Camillo-Forlanini), Leonardo De Luca(Mount Sinai Hospital), Alessandro Inno(Ospedale Sacro Cuore Don Calabria), Stefano Oliva(Istituto Tumori Bari), Nicola Maurea(Cancer Institute (WIA)), Fabio Maria Turazza, Carmine Riccio(Ospedale Sant'Anna), Andrea Tedeschi(Guglielmo da Saliceto Hospital), Alessandro Navazio(Presidio Ospedaliero), Marzia De Biasio
Cited by 1
Related Papers
Navigating the Crossroads of Coronary Artery Disease and Heart Failure
|Circulation|2006|405
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Prevalence and Prognostic Impact of Non-Cardiac Co-Morbidities in Heart Failure Outpatients with Preserved and Reduced Ejection Fraction: A Community-Based Study
|European Journal of Heart Failure|2018|174
Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy
|Critical Reviews in Oncology/Hematology|2019|164
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116